This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (143)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Revascularization  • Thrombolysis  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Randomized Controlled Trial  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

REPLACE-2 Randomized Trial

A. Michael Lincoff, MD; Neal S. Kleiman, MD; Dean J. Kereiakes, MD; Frederick Feit, MD; John A. Bittl, MD; J. Daniel Jackman, MD; Ian J. Sarembock, MB, ChB; David J. Cohen, MD; Douglas Spriggs, MD; Ramin Ebrahimi, MD; Gadi Keren, MD; Jeffrey Carr, MD; Eric A. Cohen, MD; Amadeo Betriu, MD; Walter Desmet, MD; Wolfgang Rutsch, MD; Robert G. Wilcox, MD; Pim J. de Feyter, MD; Alec Vahanian, MD; Eric J. Topol, MD; for the REPLACE-2 Investigators

JAMA. 2004;292:696-703.

Context  In the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial, bivalirudin with provisional glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition was found to be noninferior to heparin plus planned Gp IIb/IIIa blockade in the prevention of acute ischemic end points and was associated with significantly less bleeding by 30 days after percutaneous coronary intervention (PCI).

Objective  To determine whether the efficacy of bivalirudin remains comparable with that of heparin plus Gp IIb/IIIa blockade over 6 months and 1 year.

Design, Setting, and Participants  Follow-up study to 1 year of a randomized, double-blind trial conducted among 6010 patients undergoing urgent or elective PCI at 233 community or referral hospitals in 9 countries from October 2001 through August 2002.

Interventions  Patients were randomly assigned to receive intravenously bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg per hour for the duration of PCI), with provisional Gp IIb/IIIa inhibition, or to receive heparin (65 U/kg bolus), with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide). Both groups received daily aspirin and a thienopyridine for at least 30 days after PCI.

Main Outcome Measures  Incidence of death, myocardial infarction, or repeat revascularization by 6 months and death by 12 months after enrollment.

Results  At 6 months, death occurred in 1.4% of patients in the heparin plus Gp IIb/IIIa group and in 1.0% of patients in the bivalirudin group (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.43-1.14; P = .15). Myocardial infarction occurred in 7.4% and 8.2% of patients, respectively (HR, 1.12; 95% CI, 0.93-1.34; P = .24), and repeat revascularization was required in 11.4% and 12.1% of patients, respectively (HR, 1.06; 95% CI, 0.91-1.23; P = .45). By 1 year, death occurred in 2.46% of patients treated with heparin plus Gp IIb/IIIa blockade and in 1.89% of patients treated with bivalirudin (HR, 0.78; 95% CI, 0.55-1.11; P = .16). Nonsignificant trends toward lower 1-year mortality with bivalirudin were present in all patient subgroups analyzed and were of greatest magnitude among high-risk patients.

Conclusion  Long-term clinical outcome with bivalirudin and provisional Gp IIb/IIIa blockade is comparable with that of heparin plus planned Gp IIb/IIIa inhibition during contemporary PCI.

Author Affiliations: Cleveland Clinic Foundation, Cleveland, Ohio (Drs Lincoff and Topol); Baylor College of Medicine and Methodist Hospital, Houston (Dr Kleiman); the Lindner Center, Ohio Heart Health Center, Cincinnati (Dr Kereiakes); New York University School of Medicine, New York (Dr Feit); Ocala Heart Institute, Munroe Regional Medical Center, Ocala, Fla, (Dr Bittl); Tyler Cardiovascular Consultants/Trinity Mother Frances Hospital, Tyler, Tex (Dr Jackman); University of Virginia Health System, Charlottesville, Va (Dr Sarembock); Beth Israel Deaconess Medical Center, Boston, Mass (Dr D. J. Cohen); Clearwater Cardiovascular Consultants, Clearwater, Fla (Dr Spriggs); West Los Angeles VA, Los Angeles, Calif (Dr Ebrahimi); Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (Dr Keren); East Texas Medical Center, Tyler (Dr Carr); Sunnybrook & Women's College Health Sciences Center, Toronto, Ontario (Dr E. A. Cohen); University of Barcelona Hospital Clinic, Barcelona, Spain (Dr Betriu); University Hospital Gasthuisberg, Leuven, Belgium (Dr Desmet); University Clinic Charite Berlin, Berlin, Germany (Dr Rutsch); University Hospital Nottingham, Nottingham, England (Dr Wilcox); University Hospital Dijkzigt, Rotterdam, the Netherlands (Dr de Feyter); and Hopital Bichat, Paris, France (Dr Vahanian).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Nikolsky et al.
J Am Coll Cardiol 2009;54:1293-1302.
ABSTRACT | FULL TEXT  

Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention implications for contemporary practice.
Doyle et al.
J Am Coll Cardiol 2009;53:2019-2027.
ABSTRACT | FULL TEXT  

Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry
Mehta et al.
Circ Cardiovasc Interv 2009;2:222-229.
ABSTRACT | FULL TEXT  

Bleeding during percutaneous intervention: tailoring the approach to minimise risk
Kinnaird et al.
Heart 2009;95:15-19.
ABSTRACT | FULL TEXT  

Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase
Rudolph et al.
J. Pharmacol. Exp. Ther. 2008;327:324-331.
ABSTRACT | FULL TEXT  

Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
White et al.
J Am Coll Cardiol 2008;52:807-814.
ABSTRACT | FULL TEXT  

Survival Benefit With Concomitant Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Therapy at Ad Hoc Percutaneous Coronary Intervention
Gumina et al.
Mayo Clin Proc. 2008;83:995-1001.
ABSTRACT | FULL TEXT  

Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg)
Chase et al.
Heart 2008;94:1019-1025.
ABSTRACT | FULL TEXT  

Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention
Sibbing et al.
Eur Heart J 2008;29:1504-1509.
ABSTRACT | FULL TEXT  

Trends in Vascular Complications After Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention Via the Femoral Artery, 1998 to 2007
Applegate et al.
J Am Coll Cardiol Intv 2008;1:317-326.
ABSTRACT | FULL TEXT  

Bivalirudin during Primary PCI in Acute Myocardial Infarction
Stone et al.
NEJM 2008;358:2218-2230.
ABSTRACT | FULL TEXT  

Myocardial Revascularization with Percutaneous Devices
Wilson and Willerson
Card Surg Adult 2008;3:573-598.
FULL TEXT  

Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management: One-Year Results From the ACUITY Trial
Stone et al.
JAMA 2007;298:2497-2506.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Bivalirudin Versus Heparins in Reduction of Cardiac Outcomes in Acute Coronary Syndrome and Percutaneous Coronary Interventions
Singh et al.
J CARDIOVASC PHARMACOL THER 2007;12:283-291.
ABSTRACT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach
Nikolsky et al.
Eur Heart J 2007;28:1936-1945.
ABSTRACT | FULL TEXT  

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT  

Managing acute coronary syndrome: Evidence-based approaches
Spinler
Am J Health Syst Pharm 2007;64:S14-S24.
ABSTRACT | FULL TEXT  

Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Alexander et al.
Circulation 2007;115:2549-2569.
ABSTRACT | FULL TEXT  

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
Rao et al.
Eur Heart J 2007;28:1193-1204.
ABSTRACT | FULL TEXT  

Randomized Trial Comparing Same-Day Discharge With Overnight Hospital Stay After Percutaneous Coronary Intervention: Results of the Elective PCI in Outpatient Study (EPOS)
Heyde et al.
Circulation 2007;115:2299-2306.
ABSTRACT | FULL TEXT  

Anticoagulants in heart disease: current status and perspectives
De Caterina et al.
Eur Heart J 2007;0:ehl492v1-34.
FULL TEXT  

Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients
Antoniucci
Eur Heart J Suppl 2007;9:A32-A36.
ABSTRACT | FULL TEXT  

Bivalirudin for Patients with Acute Coronary Syndromes.
Stone et al.
NEJM 2006;355:2203-2216.
ABSTRACT | FULL TEXT  

Accounting for ACUITY.
Bittl
NEJM 2006;355:2249-2250.
FULL TEXT  

Measuring Troponin Elevation After Percutaneous Coronary Intervention: Ready for Prime Time?
Kleiman
J Am Coll Cardiol 2006;48:1771-1773.
FULL TEXT  

End points in clinical trials: are they moving the goalposts?
Leung and French
Heart 2006;92:870-872.
ABSTRACT | FULL TEXT  

Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk
Chew et al.
Heart 2006;92:945-950.
ABSTRACT | FULL TEXT  

The Future of an Illusion
Bittl
J Am Coll Cardiol 2006;47:2380-2383.
FULL TEXT  

Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy
Stone and Aronow
Mayo Clin Proc. 2006;81:641-652.
ABSTRACT | FULL TEXT  

Coronary revascularisation in women
Mikhail
Heart 2006;92:iii19-iii23.
ABSTRACT | FULL TEXT  

Is Clopidogrel Cardiovascular Medicine's Double-Edged Sword?
Bavry and Lincoff
Circulation 2006;113:1638-1640.
FULL TEXT  

A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study
Dyke et al.
J. Thorac. Cardiovasc. Surg. 2006;131:533-539.
ABSTRACT | FULL TEXT  

Bivalirudin Use in Carotid Endarterectomy in a Patient with Heparin-Induced Thrombocytopenia
Finks
The Annals of Pharmacotherapy 2006;40:340-343.
ABSTRACT | FULL TEXT  

Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up
Mukherjee et al.
Eur Heart J 2005;26:2524-2528.
ABSTRACT | FULL TEXT  

Peri-procedural myocardial injury: 2005 update
Herrmann
Eur Heart J 2005;26:2493-2519.
ABSTRACT | FULL TEXT  

High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin: Outcomes at 6 Months and 1 Year in the SYNERGY Trial
Mahaffey et al.
JAMA 2005;294:2594-2600.
ABSTRACT | FULL TEXT  

Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention
Sinnaeve et al.
Eur Heart J 2005;26:2396-2403.
ABSTRACT | FULL TEXT  

Bivalirudin vs Heparin in Percutaneous Coronary Intervention: A Pooled Analysis
Ebrahimi et al.
J CARDIOVASC PHARMACOL THER 2005;10:209-216.
ABSTRACT  

Percutaneous Coronary Intervention-Related Bleeding Risk Factors in Current Practice
Mathis and Gugger
The Annals of Pharmacotherapy 2005;39:1627-1632.
ABSTRACT | FULL TEXT  

Direct Thrombin Inhibitors
Di Nisio et al.
NEJM 2005;353:1028-1040.
FULL TEXT  

The Year in Non--ST-Segment Elevation Acute Coronary Syndromes
Giugliano and Braunwald
J Am Coll Cardiol 2005;46:906-919.
FULL TEXT  

What Is the Learning Curve for Carotid Artery Stenting With Neuroprotection? Analysis of 200 Consecutive Cases at an Academic Institution
Lin et al.
PERSPECT VASC SURG ENDOVASC THER 2005;17:113-123.
ABSTRACT  

Clopidogrel Pretreatment for Percutaneous Coronary Intervention: Double, Double, Dose in Trouble?
Williams
Circulation 2005;111:2019-2021.
FULL TEXT  

The year in interventional cardiology
O'Neill et al.
J Am Coll Cardiol 2005;45:1117-1134.
FULL TEXT  

Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2005;26:804-847.
FULL TEXT  

Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare Professionals From the American Heart Association
Lansky et al.
Circulation 2005;111:940-953.
ABSTRACT | FULL TEXT  

JournalScan
Malik
Heart 2004;90:1369-1370.
FULL TEXT  

Thrombophilia and New Anticoagulant Drugs
Weitz et al.
ASH Education Book 2004;2004:424-438.
ABSTRACT | FULL TEXT